Get the Daily Brief
Latest Biotech News
Acquisition: J&J buys Firefly Bio for antibody-conjugate platform
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, gaining a degrader antibody conjugate (DAC) platform. The transaction expands J&J’s options for targeted protein degradation...
Regulatory/Clinical: Sanofi halts Phase 3 riliprubart in CIDP
Sanofi will stop its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring board concluded the drug is unlikely to achieve...
Clinical development: SonoThera raises $125M for ultrasound-based gene therapy
SonoThera raised $125 million in a Series B to advance its ultrasound-based gene therapy platform into clinical testing. The company’s lead programs target Duchenne muscular dystrophy and...
Biotech IPO: Parabilis prices $670M record debut
Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million and setting a record for a venture-backed pure-play biopharma debut on Nasdaq. The oncology-focused company sold...
Funding round: Ethyreal exits stealth with $101M for thyroid eye disease
Ethyreal exited stealth with $101 million in funding to develop an anti-TSHR antibody program targeting thyroid eye disease (TED) and Graves’ disease (GD). The startup plans to enter the clinic by...
Platform: Spatial CRISPR screening maps RNA in native tissue
Researchers introduced a spatially resolved CRISPR screening method that profiles coding and non-coding RNA perturbation effects directly within native tissue contexts. The approach couples...
M&A: 10x Genomics buys Proteintech Genomics to expand proteomics
10x Genomics acquired Proteintech Genomics to strengthen its proteomics toolkit for single-cell and spatial multiomics workflows. The companies said the deal is intended to combine Proteintech’s...
Diagnostics coverage: Geneoscopy ColoSense gets Medicare coverage
Geneoscopy announced that the US Centers for Medicare and Medicaid Services revised its National Coverage Determination for colorectal cancer screening tests, adding coverage for ColoSense, the...
Regulatory/Manufacturing: CE-IVD marking for Personalis blood collection kits
Personalis secured CE-IVD marking for its blood collection kits used with its ultrasensitive NeXT Personal minimal residual disease assay. The kits—EDTA and cfDNA collection formats—now permit...
GSK deal closes a big lung-cancer gap with near-commercial assets
GlaxoSmithKline agreed to buy Nuvalent for about $10.6 billion to expand its late-stage lung-cancer franchise with two precision oncology programs under FDA review. The deal brings ROS1 inhibitor...
Sanofi stops Phase 3 CIDP trial after interim analysis flags insufficient efficacy
Sanofi halted its Phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring board concluded the trial was unlikely to achieve...
Record biotech IPO puts Parabilis on Nasdaq with $670M war chest
Parabilis Medicines priced an upsized IPO at $20 per share, raising $670 million and positioning the company for what would be the largest Nasdaq debut by a pure-play biopharma. The...
New cancer liquid biopsy pathway gets Medicare coverage for RNA-based screening
Geneoscopy said the US Centers for Medicare and Medicaid Services expanded coverage for its ColoSense stool-based RNA test within the national coverage determination for colorectal cancer...
10x Genomics buys into higher-plex proteomics with Proteintech Genomics
10x Genomics agreed to acquire Proteintech Genomics to broaden its proteomics capabilities and support integrated multiomics workflows. The deal is intended to merge 10x’s single-cell and spatial...
SonoThera raises $125M to push ultrasound-facilitated gene therapy into the clinic
SonoThera raised $125 million in a Series B to take its ultrasound-based gene therapy approach into clinical testing. The company’s non-viral platform uses microbubbles activated by ultrasound to...
Immunotherapy tool launch targets checkpoint combinations in vivo
Bio X Cell launched a ready-to-use, anti-mouse trispecific antibody in a PD-L1 × TIGIT × LAG3 format to enable combinatorial checkpoint studies in standard preclinical models. The company said the...
CNS drug target deal uses multimodal patient data for discovery
Verge Labs partnered with Tenacia Biotechnology under a CNS drug target identification agreement that uses foundation-model approaches and multimodal patient data. The data set cited in the report...
Personalis wins CE-IVD marking for blood collection kits
Personalis received CE-IVD marking for its EDTA and cfDNA blood collection kits in the European Union, enabling marketing and sale under the EU In Vitro Diagnostic Regulation. The kits are...
Allied precision diagnostics: Aignostics joins Pancreatic Cancer Action Network on spatial profiling
Aignostics and the Pancreatic Cancer Action Network (PanCAN) entered an alliance to apply Aignostics’ Atlas H&E tumor microenvironment software to spatially profile pancreatic cancer pathology...
GSK’s $10.6B push into near-approval lung cancer assets
GlaxoSmithKline agreed to acquire Nuvalent for $10.6 billion in cash, aiming to strengthen its lung cancer pipeline with two programs currently under FDA review. The deal adds ROS1 inhibitor...